Few studies have focuses on an important question based on the lower estrogen level of the body and higher ER expression in the tumor in males than in females, namely, whether MBC patients can obtain similar survival benefits from endocrine therapy as do FBC patients, particularly the post-menopausal female population. This evidence concerns the gene ESR1 and neoplasm.